Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Jazz Pharmaceuticals
National Cancer Institute (NCI)
IRCCS Ospedale San Raffaele
M.D. Anderson Cancer Center
Shanghai Changzheng Hospital
Shanghai Changzheng Hospital
National Cancer Institute (NCI)
Mayo Clinic
National Taiwan University Hospital
University of Alabama at Birmingham
Beijing Tiantan Hospital
Nationwide Children's Hospital
Case Comprehensive Cancer Center
Dana-Farber Cancer Institute
St. Justine's Hospital
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Medical College of Wisconsin
Peking Union Medical College Hospital
Tianjin Medical University Cancer Institute and Hospital
Starlight Therapeutics Inc.
Mayo Clinic
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Tianjin Medical University Cancer Institute and Hospital
University of Florida
Bristol-Myers Squibb
Hospital do Coracao
Vanderbilt-Ingram Cancer Center
Mayo Clinic
Washington University School of Medicine
Yale University
Tetragon Biosciences Ltd
St. Joseph's Hospital and Medical Center, Phoenix
Children's Oncology Group
M.D. Anderson Cancer Center
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Xuanwu Hospital, Beijing
Mayo Clinic
Assistance Publique - Hôpitaux de Paris
Beijing Bio-Targeting Therapeutics Technology Co., Ltd
Huashan Hospital
The University of Texas Health Science Center at San Antonio
Azienda Sanitaria dell'Alto Adige
University of Alabama at Birmingham
Coherence Neuro Australia Pty Limited
Washington University School of Medicine
Washington University School of Medicine
Washington University School of Medicine
NYU Langone Health
Yale University